Details for Patent: 9,388,134
✉ Email this page to a colleague
Which drugs does patent 9,388,134 protect, and when does it expire?
Patent 9,388,134 protects ENTRESTO SPRINKLE and ENTRESTO and is included in two NDAs.
Protection for ENTRESTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-one patent family members in thirty-five countries.
Summary for Patent: 9,388,134
| Title: | Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
| Abstract: | A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi. |
| Inventor(s): | Feng; Lili (Pine Brook, NJ), Godtfredsen; Sven Erik (Chatham, NJ), Sutton; Paul Allen (Parsippany, NJ), Prashad; Mahavir (Montville, NJ), Girgis; Michael J. (Montville, NJ), Hu; Bin (Green Brook, NJ), Liu; Yugang (Bridgewater, NJ), Blacklock; Thomas J. (East Hanover, NJ), Karpinski; Piotr Henryk (Lincoln Park, NJ) |
| Assignee: | NOVARTIS, AG (Basel, CH) |
| Application Number: | 14/311,788 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,388,134 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,388,134
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-001 | Apr 12, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF HEART FAILURE | ⤷ Sign Up | ||||
| Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-002 | Apr 12, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF HEART FAILURE | ⤷ Sign Up | ||||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-001 | Jul 7, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-003 | Jul 7, 2015 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,388,134
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1948158 | ⤷ Sign Up | 16C0018 | France | ⤷ Sign Up |
| European Patent Office | 1948158 | ⤷ Sign Up | 300810 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1948158 | ⤷ Sign Up | PA2016017 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1948158 | ⤷ Sign Up | CA 2016 00023 | Denmark | ⤷ Sign Up |
| European Patent Office | 1948158 | ⤷ Sign Up | 122016000038 | Germany | ⤷ Sign Up |
| European Patent Office | 1948158 | ⤷ Sign Up | 1690020-1 | Sweden | ⤷ Sign Up |
| European Patent Office | 1948158 | ⤷ Sign Up | C 2016 017 | Romania | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
